Abstract
Allergen immunotherapy is the only disease-modifying treatment for allergic diseases with proven sustained efficacy, but long treatment duration, chronic exposure to aluminum salts as well as allergic side-effects are major drawbacks. We hereby evaluate an innovative plant-based vaccine platform of in vivo assembled micro-sized bioparticles (BPs) expressing recombinant allergens for improved safety and immunogenicity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
